Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:01:36.430Z.
Calculation as of: 2026-10-06T19:01:36.430Z.
Quote observation: 2026-10-06T18:59:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 463be1a1b995a1dfb9509f80aff3bd03150ce45d2105de53d296fe87a8cca28c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Foghorn Therapeutics Inc.
Market Cap
$113.61M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $113.61M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $113.21M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | N/A |
| Genelux Corporation (GNLX)vs › | $114.64M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.53M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.58M | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.70M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.76M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
